About bayer ag - BAYRY
Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.
BAYRY At a Glance
Bayer AG
Kaiser-Wilhelm-Allee 1
Leverkusen, Nordrhein-Westfalen 51368
| Phone | 49-214-30-1 | Revenue | 51.43B | |
| Industry | Pharmaceuticals: Major | Net Income | -4,085,452,181.14 | |
| Sector | Health Technology | 2025 Sales Growth | 2.027% | |
| Fiscal Year-end | 12 / 2026 | Employees | 88,078 | |
| View SEC Filings |
BAYRY Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.83 |
| Price to Book Ratio | 1.401 |
| Price to Cash Flow Ratio | 8.28 |
| Enterprise Value to EBITDA | 6.245 |
| Enterprise Value to Sales | 1.508 |
| Total Debt to Enterprise Value | 0.567 |
BAYRY Efficiency
| Revenue/Employee | 583,970.346 |
| Income Per Employee | -46,384.479 |
| Receivables Turnover | 3.593 |
| Total Asset Turnover | 0.408 |
BAYRY Liquidity
| Current Ratio | 0.996 |
| Quick Ratio | 0.616 |
| Cash Ratio | 0.241 |
BAYRY Profitability
| Gross Margin | 59.206 |
| Operating Margin | 15.258 |
| Pretax Margin | -6.769 |
| Net Margin | -7.943 |
| Return on Assets | -3.244 |
| Return on Equity | -12.865 |
| Return on Total Capital | -5.488 |
| Return on Invested Capital | -5.937 |
BAYRY Capital Structure
| Total Debt to Total Equity | 144.302 |
| Total Debt to Total Capital | 59.067 |
| Total Debt to Total Assets | 33.852 |
| Long-Term Debt to Equity | 122.604 |
| Long-Term Debt to Total Capital | 50.185 |
Bayer Ag in the News
Bayer ordered to pay $2.1B in latest Roundup weedkiller loss
Bayer was ordered by a Georgia jury to pay about $2.1 billion to a plaintiff who claims Roundup weed killer caused his cancer. Bayer said it would appeal the verdict.
Bayer plans to shift focus away from women’s health drug research
Bayer has announced plans to shift its efforts away from women’s health to focus on diseases, cardiovascular disease, neurology, oncology and immunology.
Bayer agrees to pay $40 million to settle whistleblower claims over 3 prescription drugs
Bayer AG has agreed to pay a $40 million settlement stemming from two whistleblower lawsuits filed in 2005 and 2006 over the company's alleged use of kickbacks and false statements.
Jury sides with Bayer's Monsanto in suit claiming Roundup caused boy's cancer
A Los Angeles jury decided Tuesday that exposure to Monsanto's Roundup weedkiller was not a "substantial factor" in a 10-year-old boy developing cancer.